General Information
(Note: IPOScoop has NO CALL on this deal because it is NOT an IPO. This is a NASDAQ uplisting from the SIX Swiss Exchange Ltd., where the company’s stock trades under the symbol “MOLN.” On June 8, 2021, the last reported sale price was CHF 24.40, equivalent to US$27.14.) 
We are a clinical biopharmaceutical company applying our pioneering DARPin® product candidates to treat infectious disease, as well as in the fields of oncology and ophthalmology. We see potential in our first COVID-19 antiviral therapeutic product candidates in partnership with Novartis, and our oncology program, where we see potential in the utility and flexibility of our DARPin molecules to offer differentiated cancer treatments.
We believe that DARPin therapeutics represent a novel class of drugs. Our DARPin product candidates have been extensively tested in preclinical studies and clinical trials, including in approximately 2,000 patients in ophthalmology, infectious disease (SARS-CoV-2) and oncology.
(Note: Molecular Partners priced its NASDAQ uplisting at US$21.25 on 3 million ADS, the same number of shares in the prospectus, to raise $63.75 million.)
Employees: 152
Founded: 2004
Contact Information
Address Wagistrasse 14 8952 Zürich-Schlieren Switzerland
Phone Number +41 44 755 77 00
Web Address
Financial Information
Market Cap $872.82mil
Revenues $10.57 mil (last 12 months)
Net Income $-70.99 mil (last 12 months)
IPO Profile
Symbol MOLN
Exchange NASDAQ
Shares (millions): 3.0
Price range $21.25 - $21.25
Est. $ Volume $63.8 mil
Manager / Joint Managers J.P. Morgan/ SVB Leerink/ Cowen and Company/ RBC Capital Markets
CO-Managers Kempen & Co.
Expected To Trade: 6/16/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change